Long-term clinical observation of patients with heterozygous KIF1A variants
- PMID: 38760879
- DOI: 10.1002/ajmg.a.63656
Long-term clinical observation of patients with heterozygous KIF1A variants
Abstract
KIF1A-related disorders (KRDs) encompass recessive and dominant variants with wide clinical variability. Recent genetic investigations have expanded the clinical phenotypes of heterozygous KIF1A variants. However, there have been a few long-term observational studies of patients with heterozygous KIF1A variants. A retrospective chart review of consecutive patients diagnosed with spastic paraplegia at Miyagi Children's Hospital from 2016 to 2020 identified six patients with heterozygous KIF1A variants. To understand the long-term changes in clinical symptoms, we examined these patients in terms of their characteristics, clinical symptoms, results of electrophysiological and neuroimaging studies, and genetic testing. The median follow-up period was 30 years (4-44 years). This long-term observational study showed that early developmental delay and equinus gait, or unsteady gait, are the first signs of disease onset, appearing with the commencement of independent walking. In addition, later age-related progression was observed in spastic paraplegia, and the appearance of axonal neuropathy and reduced visual acuity were characteristic features of the late disease phenotype. Brain imaging showed age-related progression of cerebellar atrophy and the appearance of hyperintensity of optic radiation on T2WI and FLAIR imaging. Long-term follow-up revealed a pattern of steady progression and a variety of clinical symptoms, including spastic paraplegia, peripheral neuropathy, reduced visual acuity, and some degree of cerebellar ataxia. Clinical variability between patients was observed to some extent, and therefore, further studies are required to determine the phenotype-genotype correlation.
Keywords: KIF1A; cerebellar atrophy; optic radiation; peripheral neuropathy; spastic paraplegia.
© 2024 Wiley Periodicals LLC.
References
REFERENCES
-
- Anazawa, Y., Kita, T., Iguchi, R., Hayashi, K., & Niwa, S. (2022). De novo mutations in KIF1A‐associated neuronal disorder (KAND) dominant‐negatively inhibit motor activity and axonal transport of synaptic vesicle precursors. Proceedings of the National Academy of Sciences of the United States of America, 119, e2113795119.
-
- Boyle, L., Rao, L., Kaur, S., Fan, X., Mebane, C., Hamm, L., Thornton, A., Ahrendsen, J. T., Anderson, M. P., Christodoulou, J., Gennerich, A., Shen, Y., & Chung, W. K. (2021). Genotype and defects in microtubule‐based motility correlate with clinical severity in KIF1A‐associated neurological disorder. Human Genetics and Genomics Advances, 2(2), 100026.
-
- Cai, F., & Zhang, J. (1997). Study of nerve conduction and late responses in normal Chinese infants, children, and adults. Journal of Child Neurology, 12, 13–18.
-
- Cheon, C. K., Lim, S. H., Kim, Y. M., Kim, D., Lee, N. Y., Yoon, T. S., Kim, N. S., Kim, E., & Lee, J. R. (2017). Autosomal dominant transmission of complicated hereditary spastic paraplegia due to a dominant negative mutation of KIF1A, SPG30 gene. Scientific Reports, 7, 12527.
-
- Erlich, Y., Edvardson, S., Hodges, E., Zenvirt, S., Thekkat, P., Shaag, A., Dor, T., Hannon, G. J., & Elpeleg, O. (2011). Exome sequencing and disease‐network analysis of a single family implicate a mutation in KIF1A in hereditary spastic paraparesis. Genome Research, 21, 658–664.
Publication types
MeSH terms
Substances
Grants and funding
- JP23ek0109674/Japan Agency for Medical Research and Development (AMED)
- JP23ek0109549/Japan Agency for Medical Research and Development (AMED)
- JP23ek0109617/Japan Agency for Medical Research and Development (AMED)
- JP23ek0109648/Japan Agency for Medical Research and Development (AMED)
- JP23H02877/Japanese Society for the Promotion of Science KAKENHI
LinkOut - more resources
Full Text Sources